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Safety and Drug Information
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In English
From time to time drug marketing targeted at doctors –
recently also at pharmacists – arouses criticism and public
debate. There is a special feature in this type of marketing
which applies to both target groups, i.e. doctors in their role
as prescribers and pharmacy personnel as far as generic sub-
stitution is concerned. They both have an influence on the
choice of drug and therefore also on the costs borne by the
patient and society. In addition to the legal provisions gov-
erning marketing in general, drug marketing is also governed
by detailed restrictions referred to in the Medicines Act and
Decree and common to all EU countries. These provisions
limit the content of the information distributed in market-
ing as well as the means by which marketing is targeted at
various groups.
As regards drug marketing, Section 92 of the Medicines
Act lays down the framework for contacts between pharma-
ceutical companies and health care personnel as follows:
Medicinal product sales promotion targeted at health care per-
sonnel and veterinarians, such as various benefits and gifts,
must be modest in terms of economic value and must be related
to their professional activities. In the case of sales promotion
events, hospitality must be moderate and secondary in relation
to the purpose of the event, and it must not extend beyond
health care personnel. Sales promotion must not be inappropri-
ate or of such a nature that it can be considered to endanger
public trust in the impartiality of prescription, use or supply of
medicinal products.
Persons entitled to prescribe or supply medicinal products
must not ask for or accept any inducement prohibited in subsec-
tion 1 or otherwise in violation of what is provided therein.
The main aim of the provision is to ensure independ-
ence: the patient must be able to be confident that there are
professional grounds for the prescription and supply of the
drugs independent of marketing. As regards benefits, gifts
and hospitality, it is emphasised that they should be of mini-
mal economic importance and moderate. The formulation
of the provision states the guidelines in principle, but there
are no precise restrictions for normal daily activities. What is
“modest in terms of economic value” or “moderate” depends
on the generally accepted perceptions in society at the time.
Nor is the National Agency for Medicines in the Medicines
Act and Decree given the authority to issue more precise
guidelines. The limits in practice are therefore set by the
operation of control measures. 
The quotation from the Medicines Act above is followed
by a second subsection which goes on to emphasise the
responsibility of those who are the target persons of market-
ing and prohibits them from asking for or accepting any
unlawful inducement, to which usually little attention is
paid. The reform of the Medicines Act in 2004 laid down
that the responsibility for control in this issue was in the
hands of the provincial governments and the National Board
of Medicolegal Affairs.
In addition to the control exercised by the authorities,
drug marketing is also governed by effective internal control
within the industry itself. A review of the code applicable in
the industry, the Finnish Code for the Marketing of Medici-
nal Products, was carried out at the end of last year, and the
restrictions contained in it are now more precise in practice,
especially with regard to events, travel and hospitality, as well
as other inducements organised and/or offered by the indus-
try. These more precise restrictions also correspond to the
authorities’ perception of appropriate marketing restrictions,
and there are good grounds for expecting that this will lead
to reduced need for supervision by the authorities.
An increased focus on the aims and
responsibilities of drug marketing
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In English
Agranulocytosis caused by chloram-
phenicol is a generally well-known
adverse drug reaction, on account of
which chloramphenicol tablets have
not been available for decades. Never-
theless, chloramphenicol is still used in
eye ointments and, for example, in an
ointment called Iruxol which is used in
the treatment of necrotic lesions. One
gram of the ointment contains 0.6 IU
of clostridiopeptidase A and 10 mg of
chloramphenicol. 
I would like to describe a case of
agranulocytosis caused by the oint-
ment in a patient with a heel lesion.
My patient is a 90-year-old female.
She has coronary artery disease and
degenerative osteoarthritis and she is
hard of hearing. Apart from that, she
has been in good condition and self-
supporting. She suffered a fracture in
her left hip on 22.11.2004, which was
repaired using a gamma nail. The post-
operative treatment went well and the
patient became mobile again. How-
ever, a pressure sore developed in the
left heel, prolonging the hospital treat-
ment. The sore was treated with Iruxol
ointment during 28.12.2004–
10.2.2005, followed by Normgel, a
moisturising gel. Suddenly on
24.2.2005 the patient developed a
high fever with no special focal symp-
toms present. B-CRP was 294 mg/l
and the blood count revealed agranulo-
cytosis with WBC count of 0.6 x 109/l.
The patient was transferred in a septic
state for treatment at a central hospital.
The medical treatment at the transfer-
ral stage consisted of the following:
Oftagel 2.5 mg/g one drop x 4 in the
eyes, Nitrosid 5 mg x 3, Furesis 40 mg
x 2, Seloken 50 mg  x 2, Primaspan
100 mg x 1, Panadol Forte 1 g x 3,
Viscotears 2 mg/g 1 drop x 3 in the
eyes, Agiolax 5 ml x 1, Insomin 5 mg
x 1.
On arrival at the central hospital
the patient’s blood leukocytes were at
their lowest 0.7 x 109/l and the patient
was in agranulocytosis. B-CRP was at
417 mg/l on arrival. The patient had a
slight temperature and her general
condition was poor. The initial treat-
ment consisted of tobramycin and cef-
triaxone intravenously. She was also
initially given filgrastim, a granulocyte
colony-stimulating factor. The medica-
tion proved effective and B-CRP start-
ed to drop and the leukocyte values
improved. There was no growth pre-
sent in the blood cultures, but the
urine sample showed a growth of E.
coli bacteria in excess of 105. The pres-
sure sore in the heel was initially very
inflamed and painful. The situation
has improved with topical treatment
and debridements. The patient’s gener-
al condition is distinctly improved.
Treatment with acetylsalicylic acid has
been stopped at the hospital, but oth-
erwise the medical treatment continues
unchanged at the time of transferral to
a health centre. 
The patient is recovering well at
the health centre. She has regained her
usual mobility and self-supporting
lifestyle and moves about with a zim-
mer. Epithelialization of the extensive
pressure sore in the heel is taking place
gradually and plans have been made to
discharge the patient within the
following few weeks.
Discussion
There were immunological mechan-
isms involved in the agranulocytosis
caused by chloramphenicol. Toxicity is
associated with idiosyncrasy, which
means that the patient’s reaction to a
small drug dose is often different and
more intense than usual without its
being a question of hypersensitivity to
the drug. 
The practice of naming the prod-
uct, Iruxol, is unusual. It may be possi-
ble that the prescriber easily overlooks
the fact that, in addition to clostridio-
peptidase A, Iruxol ointment also con-
tains chloramphenicol, whereas Iruxol
Mono only contains the enzyme.
In addition to this case, seven other
cases of suspected ADRs in association
with the use of Iruxol have been
recorded in the ADR database of the
Finnish National Agency for Medic-
ines. All reports were associated with
skin reactions; in some cases the rash
had also spread outside the treated
area, and one patient had conjunctivi-
tis in addition. This was exacerbated
by the use of the eye ointment con-
taining chloramphenicol. In two cases,
an epicutaneous test was positive with
chloramphenicol, in one case with
Iruxol.
My own patient recovered from
agranulocytosis. She could also just as
easily have succumbed to it. In
individual practice, cases such as this
are extremely rare, but it may guide
the use of antibiotics in future
throughout the entire career of the pre-
scriber. An eye ointment containing
chloramphenicol is a conventional
method of treatment following, for
example, the removal of a foreign
object in the cornea. There is no broad
spectrum antibiotic ointment to
replace it. There are several eye drops
containing antibiotics which may be
used. But they do not have the broad
antibacterial spectrum of chloramph-
enicol.
In using of Iruxol, the allergising
effect of the ointment is worth bearing
in mind, together with the possibility
of blood count changes especially with
long-term use and in the treatment of
extensive areas.
Own observation of an ADR
Agranulocytosis caused by Iruxol ointment
Jouko Autio
General Specialist
Tervola Health Centre
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In English
Temazepam and nitrazepam of the
conventional benzodiazepines, and
short-acting midazolam and triazolam,
are classified as hypnotics and sedatives
(ATC Code N05CD). The more
recent hypnotics and sedatives include
zopiclone and zolpidem (ATC Code
N05CF) with a structure different
from benzodiazepines but with similar
properties.
Among the Nordic countries only
Iceland has a higher consumption of
hypnotics and sedatives than Finland.
There has been a rapid increase in the
consumption of hypnotics of the ben-
zodiazepine type, especially zopiclone,
in all the Nordic countries. In the rest
of the Nordic countries, along with
their increase, the consumption of the
common benzodiazepines has dropped
(Fig. 1). In Finland, in addition to
zopiclone, the consumption of the
most commonly used benzodiazepine,
temazepam, was on the increase up to
the year 2003 (Fig. 2). In 2004, for the
The growing consumption of hypnotics and
sedatives evens out
DDD/1,000 inh./day
Fig. 1. The consumption of hypnotics and sedatives in Nordic countries 1999–2003
Fig. 2. The consumption of hypnotics and sedatives in Finland 1990–2005 (* I–IV)
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first time in a decade, the consump-
tion of hypnotics and sedatives
remained at a slightly lower level com-
pared with the previous year. Only the
sales of zolpidem, with minor sales
compared with other hypnotics,
increased by 9%.
In the treatment of sleep
disturbances, it is emphasised that the
use of drugs should be as short-term as
possible. The possibility of adverse
effects and development of tolerance is
reduced by temporary and occasional
use. However, the majority of total
sales of sleeping tablets in primary care
consists of packets containing 100
tablets. The proportion of packets
intended for the recommended treat-
ment period of 7–14 days is only 3%
of the sales (Fig. 3). Only zolpidem is
sold almost exclusively in packets of 20
tablets (Fig. 4).
The consumption of all hypnotics
and sedatives is in hospital care 8%.
The proportion has slightly diminished
in recent years: it was 11% in 1999
(Fig. 5). The relatively small proport-
ion of institutional consumption may
be associated with the fact that the
consumption of antipsychotics in Fin-
land is almost double that in the other
Nordic countries. (In 2003, their con-
sumption in Sweden totalled 8.7
DDD/1,000 inhabitants/day, whereas
the corresponding figure in Finland
was 16.1). A proportion of this med-
ication is probably associated with
unspecific sedation more than with
actual treatment of psychosis.
Among benzodiazepines, those
most commonly sold, diazepam,
oxazepam and lorazepam, are included
in the group of anxiolytics in the sta-
tistics (N05BA), even though a
proportion of their use is at least in
part due to sleeping difficulties. Their
consumption has not varied in any sig-
nificant way in recent years.
Fig. 5. The consumption of hypnotics and sedatives in outpatient and institutional
care in Finland 1999–2005 (* I–IV)
Fig. 4. The consumption of most common hypnotics and sedatives in the package
sizes in Finland 1999–2005 (* I–IV)
Fig. 3. The consumption of hypnotics and sedatives in the package sizes 
in Finland 1999–2005 (* I–IV)
The consumption of medicines is pre-
sented in daily doses, in proportion to
the population and time. The figure
represents, in promilles, the proportion
of the population that has used the
defined daily dose of the medicinal
substance every day.
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The EU-wide regulatory framework
within mutual recognition procedures
(MRP) is based on the co-operation
and sharing of the regulatory workload
between 25 EU Member States and 3
EEA countries. The National Agency
for Medicines (NAM) in Finland is
willing to handle its share of the com-
mon regulatory workload. However,
every national competent authority, as
NAM, has limitations to accommodate
large and unexpected fluctuations in
the number of Marketing Authorisa-
tion Applications (MAAs).
During 2003 and 2004 NAM has
granted app. 500 national marketing
authorisations per year. In 2004, the
number of MRP procedures with Fin-
land as reference member state (RMS)
has been expanded to over 150 proce-
dures (30 % of all MRP procedures in
the EU). Due to the large number of
MAAs for generic products during
recent months the NAM has currently
over 800 pending applications for mar-
keting authorisation. Most applicants
are planning a Mutual Recognition
Procedure after national authorisation
in Finland. A considerable amount of
these products are not planned to be
marketed in Finland.
There is a serious concern that this
extremely heavy workload will
definitely lead to delays and longer
processing times for all marketing
authorisation procedures in Finland.
Therefore, NAM is obliged to adjust
its functions to cope with the
unexpected workload due to MAAs of
generic products intended for other
markets. According to NAM’s opinion
the applicants should submit their
future MAAs for generic products pri-
marily to those Member States to
which their products are de facto
targeted. 
As a part of these new functional mea-
sures and guidance: 
The applicants are asked to provide
a list of planned national or decentral-
ised submissions during 2005 to the
national marketing authorisation pro-
cedure in Finland. The following
information should be included to the
list if possible:
- Drug substance, strengths and
pharmaceutical forms 
- Number of trade names
(duplicates)
- Plans for MRP or decentralised
procedures (DCP) incl. concerned
member states (CMSs) and draft
time schedule.
When the NAM is planned to act
as the RMS, the applicant should con-
tact prior to the national or decentral-
ised submission in order to draw up a
time plan. 
The applicants are asked to provide
information concerning the schedule
for marketing introduction in Finland
for each individual MA (pending
MAAs as well as planned submissions).
The information is extremely impor-
tant for NAM to prioritize assessment
duties. This information will be also
taken account to analyse the
consequences of the new so-called Sun-
set Clause1 coming to operation since
30 October 2005. In the future this
may risk the validity of Finnish mar-
keting authorisations and consequently
the grounds for Finland to act as RMS
for those medicinal products. 
The NAM will concentrate to keep
the processing time of each individual
national authorisation in 210 days. 
To get more resources for processing of
applications in the order of sub-
mission, so-called clones or duplexes
are not any more processed by fast
track. The applicants are asked to take
account the chance in the procedure of
the NAM in the future submissions.
The applicant can help to cut pro-
cessing times by submitting complete
and well-compiled applications. How-
ever, to make the discussions more effi-
cient between the NAM and the appli-
cant, especially in clinical and pharma-
ceutical issues concerning SPC and
PIL, the applicants are asked to
provide a contact point of the
Finnish/Swedish speaking person
authorised for communication with
the NAM. 
The National Agency for Medi-
cines is committed to contribute and
to co-operate in the national and
European marketing authorisation pro-
cedures in the best possible ways and
according to the legislative frame-
works. However, the new functional
and practical measures and guidance
above are regarded necessary for the
purpose of keeping the regulatory
processes in control and in rational
management.  
1 Marketing authorisation ceased to be valid if
product is not marketed within three years or
for three consecutive years. 
For further information please contact
Dr. Jussi Holmalahti, by e-mail
(jussi.holmalahti@nam.fi).
New functional guidance for generic applications 
In English
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Safety of products containing materials of 
human origin
In English
The use as transplants for various pur-
poses of organs and tissues, both fresh
and stored in tissue banks, including
blood and its derivatives, is well estab-
lished. The same applies  to various
bio-prostheses originating from human
tissue. New technologies offer a fast-
growing selection of different
techniques for the utilisation of mate-
rials of human origin. It is likely that
clinical practices will in the near future
be dominated by three different cate-
gories of technology.
One of these is cell therapy, which
means the placing of live cells in a
human body to produce natural sub-
stances, in which the patient is lacking
due to various clinical situations and
injuries. Another form of technology is
gene therapy, which implies the trans-
fer of genes to live cells either in order
to produce a gene product missing in
the cell, or a product previously
unknown to the cell, with the aim of
producing some totally new function.
The third form of treatment of the
future is tissue engineering, in which
cultured cells are used to replace the
activity of cell masses which normally
act in a co-ordinated fashion. The bor-
derline between these technologies is
artificial. It would appear at present
that all three are developing hand in
hand – which is also supported by the
fact that researchers are often using all
three at the same time depending on
the type of function they aim to pro-
duce.
The selection of products based on
materials of human origin is growing
on the markets. The growth is guaran-
teed by the ongoing intensive interna-
tional research and product develop-
ment in the field. A number of surveys
of several applications have been pub-
lished recently (1, 2, 3). A review com-
missioned by the European Commis-
sion well reflects the market situation
and future prospects of the sector well
(4).
Risks involved with new 
technologies
Assessment of the risks involved with
products containing materials of
human origin requires familiarity with
the whole manufacturing process
including the intermediate stages and
the operators responsible for them.
Some of the risks involved are of a
type where experience already exists,
e.g. the use of transplants, but where
additional investigation is necessary in
order to make the routines associated
with therapies using tissue engineering
technology safe. This group includes,
for example, risks of rejection and
infection. The risk of infection is the
most important individual risk factor
associated with tissue engineering tech-
nology products. Control of infection
should be very strict during the entire
handling process of cells, all the way
from cell recovery and screening of
materials. The biggest risk of infection
in the use of human cells is cell conta-
mination and the transfer of prions,
viruses and mycoplasmata from the
donor to the recipient. The products
are considered to be associated with
several risks, of which previous health
care products have offered no experi-
ence. Unknown risks include, for
example, the effects of cell modific-
ation, the use of scaffolding in the
body, the cancer risk associated with
stem cells and the risk of transfer of
xenogenic infections (zoonoses) when
using materials of animal origin. The
safety of products is, of course, very
much dependent on the procurement
of materials of human origin and on a
well controlled manufacturing process.
Directives to ensure safety
The increased therapeutic use of the
materials discussed above, concern
about the quality and safety of the
products, including ethical viewpoints
associated with the issues, has alerted
the European Commission (5). There
is a pressing demand to harmonise the
requirements and measures of control
among the EU member states.
The Directive 2004/23/EC issued
in March 2004 by the European Par-
liament and Council sets out the stan-
dards of quality and safety for dona-
tion, procurement, testing, processing,
preservation, storage and distribution
of human tissues and cells (6). The
provisions of the Directive should be
incorporated in the national legislation
by the 7th of April 2006. The provi-
sions will set out the selection criteria
for tissue and/or cell donors, for exam-
ple, and the obligatory laboratory tests
for donors, as well as the procedures to
be followed in the procurement of cells
There is intensive development of
products containing materials of
human origin, and the products
are commercially available world-
wide. They are expected to offer
completely novel opportunities in
the treatment of several diseases.
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and/or tissues and in their reception at
tissue establish-ments. Standards will
apply and will be issued for the opera-
tion of tissue establishments and their
control procedures. In practical terms,
the provisions above will set the mini-
mum standards for tissue bank services
(tissue establish-ments) including
requirements that apply for source
materials of products engineered from
human tissue and for cell therapy
products with regard to donation, pro-
curement and testing.
In 2000 the European Commission
started the preparation of an EU regu-
lation on products engineered from
human tissue with the aim of setting
up provisions for products lying in the
area between medical devices and med-
icines. The industry in that area has
already for a decade tried to achieve
harmonised European requirements to
supplant the varying national require-
ments. The Commission has published
its most recent proposals for regulating
the intermediate area (7). There is
strong evidence that the provisions will
be based on the control procedures
governing medicines. The aim is to
group all the cell and gene therapy
products already classified as medicinal
products and the unregulated products
engineered from human tissue into a
single entity (Advanced Therapies).
The interest groups are requested to
express their views about the Commis-
sion’s proposal before the 20th of June
2005.
It is the legislator’s duty to ensure
that the national legislation provides
flawless protection for patient safety. It
is necessary to have a forward-looking
approach, to identify the entities and
to ensure that the necessary co-ordina-
tion is in place for the preparation of
EC legislation. In Finland, the
Ministry of Social Affairs and Health
prepares the statutes and provisions.
According to the performance target
agreement between the Ministry of
Social Affairs and Health and the
National Agency for Medicines
(NAM) in 2004, NAM has prepared a
report on the safety of products con-
taining materials of human origin. The
report is based on literature studies
and is a compilation of material pro-
duced by different sources in recent
years (8). As a supervisory authority of
medicines and medical devices and
within the limits of its own expertise
NAM assists the Ministry in the prepa-
ration of statutes. Biological medicinal
products, especially biotechnology
products, cell therapy products and
gene therapy products, are the areas on
which NAM will focus in its presence
within the EU.
Literature
1. Viljanen, V., Terveydenhuollon laitteissa ja
tarvikkeissa käytettävät ihmisalkuperää olevat
biomateriaalit, Lääkelaitoksen julkaisusarja
5/2003, http://www.nam.fi/uploads/Biomate-
riaalijulkaisut/Ihmisalkuperaa.pdf
2. E. A. Mäkelä, R. Uusitalo, T. Kivelä, A.
Papp: Kudossiirteet ihmisten varaosina,
Duodecim 2004;120:1410-8.
3. H. Lagus, J. Vuola: Keinotekoiset ihon
korvikkeet, Duodecim 2004;120:1977-85
4. A-K Bock, D. Ibarreta, E. Rodriguez-Cere-
zo: Human tissue-engineered products - To-
day’s markets and future prospects, Report
EUR 21000 EN, European Commission,
Joint Research Centre (DG JRC), Institute
for Prospective Technological Studies, Octo-
ber 2003, ftp://ftp.jrc.es/pub/EUR-doc/
eur21000en.pdf
5. Opinion on the state of the art concerning
tissue engineering, European Commission,
The Scientific Committee on Medicinal Pro-
ducts and Medical Devices, October 2001,
http://europa.eu.int/comm/food/fs/sc/scmp/o
ut37_en.pdf
6. Directive 2004/23/EC of the European
Parliament and the Council of 31 March
2004 on setting standards of quality and safe-
ty for the donation, procurement, testing,
processing, preservation, storage and distribu-
tion of human tissues and cells.  
7. European Commission, Advanced Thera-
pies, http://pharmacos.eudra.org/F3/human-
tissue/index.htm
8. Selvitys ihmisperäistä materiaalia sisältä-
vien tuotteiden turvallisuudesta, Lääkelaitos
2005, http://www.nam.fi/uploads/Ajankoh-
taista/selvitys_Ihmisalkuperaisten_tuot-
teiden_turvallisuus.pdf
Translation Mervi Moisander
